Health Care & Life Sciences » Pharmaceuticals | Hanmi Pharmaceutical Co. Ltd.

Hanmi Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
730,134
761,280
1,317,535
882,725
916,586
1,015,962
Cost of Goods Sold (COGS) incl. D&A
322,948
347,622
432,297
440,202
404,953
463,464
Gross Income
407,185
413,658
885,237
442,522
511,633
552,498
SG&A Expense
341,427
375,059
608,265
411,579
429,469
468,851
EBIT
61,895
34,452
211,800
26,772
82,164
83,646
Unusual Expense
2,450
2,873
13,406
43,185
4,636
12,965
Non Operating Income/Expense
7,585
13,373
22,448
31,494
11,732
5,167
Interest Expense
14,876
12,089
12,266
10,074
10,698
19,414
Pretax Income
54,829
36,461
209,585
7,998
58,850
50,355
Income Tax
4,295
6,834
47,524
22,302
10,124
16,199
Consolidated Net Income
50,534
43,295
162,060
30,300
68,974
34,156
Net Income
43,933
35,510
154,443
23,326
60,434
24,891
Net Income After Extraordinaries
43,933
35,510
154,443
23,326
60,434
24,891
Net Income Available to Common
43,933
35,510
154,443
23,326
60,434
24,891
EPS (Basic)
4,328.89
3,305.70
13,588.05
2,054.24
5,482.00
2,158
Basic Shares Outstanding
10
11
11
11
11
12
EPS (Diluted)
4,329.29
3,305.31
13,587.63
2,053.94
5,482.03
2,157.63
Diluted Shares Outstanding
10
11
11
11
11
12
EBITDA
89,438
60,316
261,931
65,547
119,135
130,767
Other Operating Expense
3,863
4,147
65,172
4,172
-
-
Non-Operating Interest Income
2,675
3,599
1,008
2,991
3,752
4,253
Minority Interest Expense
6,601
7,786
7,617
6,974
8,539
9,265

About Hanmi Pharmaceutical Co.

View Profile
Address
214 Muha-ro
Hwaseong GY 18536
Korea, Republic Of
Employees -
Website http://www.hanmipharm.com
Updated 07/08/2019
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong-si, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.